All relevant data are within the paper and its Supporting Information files.

Introduction {#sec007}
============

Pelvic ring injuries can be seen as one of the most serious traumatic injuries with large consequences for the patients' daily life. Apart from the substantial mortality rates \[[@pone.0233226.ref001],[@pone.0233226.ref002]\], principally in high-energy trauma, these injuries coincide with long periods of impaired mobilization and intense rehabilitation. In addition, pelvic ring injuries are increasingly caused by low-energy trauma in the frail elderly. Injury types vary from stable type A fractures, usually treated nonoperatively, to highly unstable type C fractures, often demanding operative fixation and long term recovery. Despite this, adequate prospective follow-up studies, both on short-term and long-term outcome, on pelvic ring injuries are lacking.

Many factors that characterise a patient's health status cannot be observed, measured with a device, or analysed with even the most sophisticated imaging methods. How a patient feels and performs remains largely impenetrable to devices \[[@pone.0233226.ref003]\]. The growing focus on patient-centred care has resulted in a shift in terms of outcome assessment and the increasing use of Patient-Reported Outcome Measurements (PROMs). These questionnaires seek to assess the influence of the patients' condition on their daily functioning and emotional status, and can provide critical information to enhance patient-centred health care \[[@pone.0233226.ref004]\]. Conceptually, PROMs can be viewed either as a 'tool for evaluation' or as a 'mechanism for improvement'.

No actual guidance exists for appropriate PROM-based assessment after pelvic ring injuries. Hence, the problem arises with regard to the long list of different PROMs used, many of which have no proof of being valid or reliable either. Lefaivre et al. \[[@pone.0233226.ref005]\] showed that many different types of generic outcome instruments as well as pelvis-specific measures are used to assess the outcomes after pelvic ring injuries. Besides, due to the wide variety in types of pelvic ring injuries and the variability in treatment strategy, outcomes are hard to compare, leaving physicians, researchers and patients in doubt about the actual outcomes following these injuries.

In this perspective, the main objective of the present systematic review was to identify and analyse published studies, thereby providing a representative overview of the outcomes in terms of patient-reported physical functioning and quality of life following pelvic ring injuries. Moreover, following the results of this review, our aim was to highlight whether changes can be made for future research in order to properly evaluate the consequences of these severe injuries.

Methods {#sec008}
=======

For this systematic review the PRISMA method \[[@pone.0233226.ref006]\] for literature collection and manuscript construction was followed. The review protocol has been registered in PROSPERO International prospective register of systematic reviews under registration number CRD42019129176.

Identification of studies: Search strategy {#sec009}
------------------------------------------

The search strategy sought to retrieve references relating to physical functioning and quality of life after pelvic ring injuries. Therefore, the items "pelvis", "injury" and "outcome" were combined to develop the search strategy. Searches used medical subject headings (MeSH terms) and free text searching to combine terms specific to pelvic ring injuries with terms relevant to PROMs evaluation. The full electronic search strategy was developed in collaboration with an experienced medical librarian and is presented in [Table 1](#pone.0233226.t001){ref-type="table"}. Two databases were searched to identify original articles: MEDLINE-PubMed (2008-15-04-2019) and Ovid-EMBASE (2008-15-04-2019).

10.1371/journal.pone.0233226.t001

###### Search strings by database.
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  Database         Search string
  ---------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  MEDLINE-PubMed   (((\"Pelvis\"\[Mesh:NoExp\] OR \"Sacrum\"\[Mesh\] OR \"Sacroiliac Joint\"\[Mesh\] OR \"Pubic Bone\"\[Mesh\] OR \"Pelvic Bones\"\[Mesh\] OR pelvic\[tiab\] OR pelvis\[tiab\] OR sacrum\[tiab\] OR sacral\[tiab\] OR sacroiliac\[tiab\] OR pubic\[tiab\]) AND (\"Wounds and Injuries\"\[Mesh\] OR injur\*\[tiab\] OR fractur\*\[tiab\] OR trauma\*\[tiab\]) AND (\"Quality of Life\"\[Mesh\] OR quality of life\[tiab\] OR \"Recovery of Function\"\[Mesh\] OR functional status\[tiab\] OR functional outcome\*\[tiab\] OR physical function\*\[tiab\] OR \"Patient Outcome Assessment\"\[Mesh\] OR patient reported outcome\*\[tiab\] OR outcome assessment\[tiab\] OR SMFA\[tiab\] OR short musculoskeletal function assessment\[tiab\] OR EQ-5D\[tiab\] OR euroqol\[tiab\] OR SF-36\[tiab\] OR short form\[tiab\] OR SF-12\[tiab\] OR majeed\[tiab\] OR merle d\'aubigne\[tiab\] OR (IPS\[tiab\] OR iowa\[tiab\])) NOT case reports\[pt\]) AND (\"2008/01/01\"\[PDat\]: \"3000/12/31\"\[PDat\]))
  Ovid-EMBASE      (\'pelvis\'/de OR \'sacrum\'/exp OR \'sacroiliac joint\'/exp OR \'pubic bone\'/exp OR \'pelvis fracture\'/exp OR \'pelvis injury\'/exp OR \'sacral fracture\'/exp OR pelvic:ti,ab OR pelvis:ti,ab OR sacrum:ti,ab OR sacral:ti,ab OR sacroiliac:ti,ab OR pubic:ti,ab) AND (\'injury\'/exp OR injur\*;ti,ab OR fractur\*:ti,ab OR trauma\*:ti,ab) AND (\'quality of life\'/exp OR \'convalescence\'/exp OR \'patient-reported outcome\'/exp OR \'patient outcome assessment\':ti,ab OR \'patient reported outcome\*\':ti,ab OR \'quality of life\':ti,ab OR \'functional status\':ti,ab OR \'functional outcome\*\':ti,ab OR \'physical function\*\':ti,ab OR \'outcome assessment\':ti,ab OR smfa:ti,ab OR \'short musculoskeletal function assessment\':ti,ab OR \'eq 5d\':ti,ab OR euroqol:ti,ab OR \'sf 36\':ti,ab OR \'short form\':ti,ab OR \'sf 12\':ti,ab OR majeed:ti,ab OR (merle:ti,ab AND aubigne:ti,ab) OR (ips:ti,ab AND iowa:ti,ab)) AND \[embase\]/lim AND \[2008--2018\]/py NOT \'case report\'/de NOT \'conference abstract\'/it

Inclusion and exclusion criteria and procedure {#sec010}
----------------------------------------------

Eligible studies included patients aged 18 years or older with a pelvic ring injury. Studies that focused on the outcomes after nonoperative as well as operative treatment were eligible. The outcome measures used should include patient-reported outcome measures (PROMs). Except for case studies and conference abstracts, all study designs were accepted for inclusion. Concerning language, studies written in English, German, Spanish, French and Dutch were included. There was no limitation on the search by publication status. Studies on geriatric fractures or fragility fractures were excluded. Studies with a sample size of less than 20 patients in follow-up were excluded, because PROMs results based on so few patients seem unreliable. Moreover, studies that included outcomes after both pelvic ring injuries and acetabular fractures and that did not differentiate between these injuries in terms of outcomes, were excluded as well. The study selection was performed in two screening phases: 1) title and abstract screening, and 2) full text screening. Both selection phases were independently performed by the same researchers (HB, IR).

Data extraction {#sec011}
---------------

Data extraction was performed in sequence using a standardized data extraction spreadsheet developed prior to data extraction, for evaluating physical functioning and quality of life after pelvic ring injuries. During both selection phases, articles were selected on the basis of language, number of patients, age of patients, population (pelvic ring injury and human/non-human), study type and use of PROMs. Relevant data from the included articles were extracted by the senior author including the 1) names of the authors, 2) year of publication, 3) study design, 4) number of patients in follow-up, 5) type of pelvic injury, 6) details on type of treatment, 7) type of PROMs, and 8) outcome of PROMs. In case of discrepancies during any of the stages, the topic of disagreement was discussed within the entire review team (HB, IR, FIJ, KtD) in order to resolve disagreements.

PROMs {#sec012}
-----

The variables for which data were sought included all PROMs used to assess physical functioning and quality of life after pelvic ring injuries. These included the disease-specific Majeed Pelvis Score, Iowa Pelvic Score, Pelvic Outcome Score and Merle D'Aubigne-Postel score, as well as the generic Musculoskeletal Function Assessment, the Short Musculoskeletal Function Assessment, Short Form-36, Short Form-12 and EuroQuol-5D. A description of each of these PROMs can be found in [S1 File](#pone.0233226.s001){ref-type="supplementary-material"}.

Assessment of methodological quality {#sec013}
------------------------------------

Two authors (HB, IR) independently rated the methodological quality and risk of bias for each study by using a quality assessment tool developed by the McMaster University Occupational Therapy Evidence-Based Practice Research Group \[[@pone.0233226.ref007]\]. The Modified McMaster Critical Review form for Quantitive Studies consists of nine categories: citation, study purpose, literature, design, sample, outcomes, intervention, results, and conclusions and implications. This review form is appropriate to assess RCTs, cohort studies, single-case designs, before- and after-designs, case control studies, cross-sectional studies and case studies. The guidelines established by Law et al. \[[@pone.0233226.ref007]\] were utilized for the quality assessment. Every item was answered with 'yes; 1 point', 'no; 0 points', 'not addressed; 0 points' or 'not applicable (N/A); no points given'. The sum of these outcomes predicted the overall quality of the study assessed, ranging from 0 to 14 for RCTs and 0 to 12 for other study designs. The final score is given as the percentage of the maximum score. Qualitative assessment of intervention was not performed for the reason that this was irrelevant for the purpose of this review. Disagreements between the review authors were resolved through discussion until consensus was reached.

Strategy for data synthesis {#sec014}
---------------------------

Data synthesis involved the comparison, combination, and summary of findings. Efforts were made to retrieve missing data on follow-up duration and missing scores on the questionnaires, by contacting the corresponding authors. Data is presented as part of a narrative synthesis, involving text and tables. The data are grouped according to the time of follow-up and the outcomes of the different types of PROMs that were used.

Statistics {#sec015}
----------

The results of the various questionnaires are shown according to the standards of the specific questionnaire, either as number with percentage or as mean with standard deviation or median with range or interquartile range (IQR). Pooled means and standard deviations were manually calculated for the complete cohort of every study in case the outcomes of the PROMs were provided for two or more groups.

Results {#sec016}
=======

Selection of studies {#sec017}
--------------------

The initial searches (conducted from January 2008 to April 15^th^ 2019) generated 2577 articles. Following title and abstract assessment, 95 articles were reviewed in full text. A total of 46 articles were included in the review, of which most (N = 22) were cross-sectional studies, followed by case-control studies (N = 12), cohort studies (N = 10), one RCT and one combination of a cohort and cross-sectional study. [Fig 1](#pone.0233226.g001){ref-type="fig"} demonstrates a flowchart of the inclusion procedure.

![Flow diagram according to the PRISMA method.](pone.0233226.g001){#pone.0233226.g001}

Patient and injury characteristics {#sec018}
----------------------------------

Overall, data of a total of 3049 patients were reported in the studies. The number of patients included in the studies varied widely, from as little as 20 patients \[[@pone.0233226.ref008]\] up to as much as 263 patients \[[@pone.0233226.ref009]\]. However, most studies were relatively small; only seven studies \[[@pone.0233226.ref009]--[@pone.0233226.ref015]\] included more than 100 patients and more than half reported on even less than 50 patients. Thirty-eight studies focused on unstable pelvic ring injuries (Type B and/or Type C according to the AO classification system \[[@pone.0233226.ref016]\]), whereas only six studies included all types of pelvic ring injuries \[[@pone.0233226.ref010],[@pone.0233226.ref012],[@pone.0233226.ref015],[@pone.0233226.ref017]--[@pone.0233226.ref019]\]. Two studies focused on the outcomes after sacral fractures \[[@pone.0233226.ref020],[@pone.0233226.ref021]\]. Both nonoperative treatment as well as several operative techniques were applied to treat the patients, although no study solely focused on the outcomes after nonoperative treatment. Operative techniques varied from external fixation to internal fixation with osteosynthesis plates to percutaneous fixation and other minimally invasive techniques. All included studies are described in [Table 2](#pone.0233226.t002){ref-type="table"}.

10.1371/journal.pone.0233226.t002

###### Study characteristics.
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  No.                                                                               Study                                            N     Method   Study period   Injury type (AO/OTA) [^‡^](#t002fn002){ref-type="table-fn"}   Interventions                                                                                                                                                    PROMs                     Follow-up in months
  --------------------------------------------------------------------------------- ------------------------------------------------ ----- -------- -------------- ------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------- ------------------------------------------------------------
  1                                                                                 Abhishek et al. \[[@pone.0233226.ref022]\]       41    CS       2007--2014     B, C                                                          Percutaneous ilio-sacral screw fixation                                                                                                                          MPS                       12
  2                                                                                 Adelved et al. \[[@pone.0233226.ref023]\]        28    CS/CSS   1996--2001     C                                                             Surgical treatment with open or closed reduction                                                                                                                 SF-36                     12 (short FU) and 128 (mean; range 97--161) (long-term FU)
  3                                                                                 Ayvaz et al. \[[@pone.0233226.ref008]\]          20    CSS      2004--2006     B, C                                                          Closed reduction and percutaneous fixation                                                                                                                       SF-36, MPS, IPS, POS      33 (mean; range 24--52)
  4                                                                                 Banierink et al. \[[@pone.0233226.ref012]\]      192   CSS      2007--2016     A, B and C                                                    Nonoperative and operative treatment                                                                                                                             SMFA-NL, EQ-5D            53 (mean; range 12--120)
  5                                                                                 Bastian et al. \[[@pone.0233226.ref024]\]        63    CSS      2004--2013     B, C                                                          Anterior fixation by modified Stoppa approach                                                                                                                    MPS                       40 (mean; range 12--96)
  6                                                                                 Bi et al. \[[@pone.0233226.ref025]\]             43    CCS      2012--2016     B                                                             S: Modified pedicle screw-rod fixation                                                                                                                           MPS                       12
  C: Anterior pelvic external fixation                                                                                                                                                                                                                                                                                                                                                                                      
  7                                                                                 Borozda et al. \[[@pone.0233226.ref026]\]        28    CS       2009--2013     C                                                             External fixation with separate anterior and posterior modules                                                                                                   MPS                       12
  8                                                                                 Bott et al. \[[@pone.0233226.ref027]\]           74    CS       1994--2005     B, C                                                          Surgical treatment                                                                                                                                               SF-36, EQ-5D              180 (mean; range 132--264)
  9                                                                                 Brouwers et al. \[[@pone.0233226.ref010]\]       195   CSS      2011--2015     A, B and C                                                    Nonoperative or surgical treatment                                                                                                                               MPS, EQ-5D                29 (mean; range 6--61)
  10                                                                                Chen et al. \[[@pone.0233226.ref028]\]           58    CCS      2002--2007     C                                                             S: Internal fixation with percutaneous reconstruction plate via posterior approach                                                                               MPS                       21 (mean; range 12--36)
  C: Internal fixation with percutaneous sacroiliac screws via posterior approach                                                                                                                                                                                                                                                                                                                                           
  11                                                                                Chen et al. \[[@pone.0233226.ref029]\]           21    CSS      2006--2009     B                                                             Endobutton technique for dynamic fixation of traumatic symphysis pubis disruption                                                                                MPS                       23 (mean; range 18--26)
  12                                                                                Chen et al. \[[@pone.0233226.ref030]\]           32    CCS      2002--2009     B, C                                                          S: Percutaneous iliosacral screw fixation                                                                                                                        SF-36, MPS                12
  C: Nonoperative treatment                                                                                                                                                                                                                                                                                                                                                                                                 
  13                                                                                Dienstknecht et al. \[[@pone.0233226.ref031]\]   62    CSS      2000--2007     C                                                             Minimally invasive stabilizing system                                                                                                                            POS                       37 (mean; range 36--42)
  14                                                                                Feng et al. \[[@pone.0233226.ref032]\]           26    CCS      2009--2013     B                                                             S: percutaneous fixation of traumatic pubic symphysis diastasis using a TightRope and external fixator                                                           MPS                       15 (mean; range 12--20)
  C: percutaneous cannulated screw fixation                                                                                                                                                                                                                                                                                                                                                                                 
  15                                                                                Frietman et al. \[[@pone.0233226.ref019]\]       37    CSS      2003--2013     A, B and C                                                    Symphyseal plating                                                                                                                                               SF-36, MPS                34 (median; range 12--109)
  16                                                                                Ghosh et al. \[[@pone.0233226.ref033]\]          75    CS       2015--2016     B, C                                                          Nonoperative or surgical                                                                                                                                         MPS                       6
  17                                                                                Grubor et al. \[[@pone.0233226.ref018]\]         47    CSS      1999--2009     A, B and C                                                    Nonoperative (sling, side-lying, resting) or Surgically (internal fixation, AO plates and screws) through Emile-Letournel's, suprapubic or sacroiliac approach   Merle d'Aubigne- Postel   ≥18 after trauma
  18                                                                                Hoch et al. \[[@pone.0233226.ref014]\]           128   CS       2004--2010     B                                                             Nonoperative and operative (minimally invasive posterior pelvic ring procedures).                                                                                SF-12, EQ-5D              24
  19                                                                                Hoffman et al. \[[@pone.0233226.ref013]\]        119   CS       2000--2010     B                                                             Nonoperative and operative (open or closed reduction and internal fixation)                                                                                      SMFA                      6, 12 and 24
  20                                                                                Holstein et al. \[[@pone.0233226.ref015]\]       172   CSS      2004--2011     A, B and C                                                    Nonoperative and operative                                                                                                                                       EQ-5D                     36 (median; range 12--72)
  21                                                                                Hua et al. \[[@pone.0233226.ref034]\]            23    CSS      2012--2015     B, C                                                          Minimally invasive interior internal pelvic fixator (INFIX) with or without a posterior pedicle screw-rod fixator                                                MPS                       14 (mean; range 6--27)
  22                                                                                Kokubo et al. \[[@pone.0233226.ref035]\]         82    CSS      1991--2010     B, C                                                          Nonoperative, external fixator or surgical                                                                                                                       MPS                       12 (short FU) and 89 (mean; range 26--187) (long-term FU)
  23                                                                                Li et al. \[[@pone.0233226.ref036]\]             64    CCS      2004--2006     C                                                             S: Surgical treatment with use of 3D printing model of the fracture                                                                                              MPS                       12 and 144
  C: Without 3D printing model                                                                                                                                                                                                                                                                                                                                                                                              
  24                                                                                Li et al. \[[@pone.0233226.ref037]\]             47    CSS      2007--2014     C                                                             Iliac screw fixation in the posterior column of the ilium                                                                                                        MPS                       21 (mean; range 12--36)
  25                                                                                Liu et al. \[[@pone.0233226.ref038]\]            45    CCS      2016--2017     B, C                                                          S: Robot-assisted percutaneous screw placement combined with pelvic internal fixator                                                                             MPS                       5 (mean; range 4--12)
  C: Percutaneous screw placement using conventional fluoroscopic imaging                                                                                                                                                                                                                                                                                                                                                   
  26                                                                                Lybrand et al. \[[@pone.0233226.ref039]\]        54    CSS      2000--2013     B, C                                                          Symphyseal fixation                                                                                                                                              EQ-5D, MPS                84 (mean; range 24--168)
  27                                                                                Ma et al. \[[@pone.0233226.ref009]\]             263   CCS      2009--2015     B, C                                                          S: Internal fixation                                                                                                                                             MPS                       6
  C: External fixation                                                                                                                                                                                                                                                                                                                                                                                                      
  28                                                                                Muller et al. \[[@pone.0233226.ref040]\]         36    CS       2004--2012     C                                                             Anterior subcutaneous internal fixator (ASIF)                                                                                                                    SF-12, POS                18
  29                                                                                Nie et al. \[[@pone.0233226.ref041]\]            30    CSS      2015--2017     B, C                                                          Minimally invasive surgery assisted by 3D printing technology                                                                                                    MPS                       10 (mean; range 4--16)
  30                                                                                Oh et al. \[[@pone.0233226.ref042]\]             22    CSS      2008--2012     B, C                                                          Anterior plate fixation through Stoppa approach                                                                                                                  Merle d'Aubigne- Postel   16 (mean; range 10--51)
  31                                                                                Park et al. \[[@pone.0233226.ref043]\]           64    CCS      2009--2013     B, C                                                          S: ORIF with plate fixation and additional tension band wiring                                                                                                   MPS                       34 (mean; range 26--39)
  C: ORIF with plate fixation alone                                                                                                                                                                                                                                                                                                                                                                                         
  32                                                                                Schmitz et al. \[[@pone.0233226.ref017]\]        55    CSS      2004--2014     A, B and C                                                    Nonoperative and operative fixation                                                                                                                              SF-36, EQ-5D              50 (mean; SD 35)
  33                                                                                Schweitzer et al. \[[@pone.0233226.ref044]\]     71    CSS      1998--2005     B, C                                                          Closed reduction and iliosacral percutaneous fixation                                                                                                            MPS                       31 (mean; range 12--96)
  34                                                                                Shui et al. \[[@pone.0233226.ref011]\]           117   CSS      2003--2013     B, C                                                          Percutaneous screw fixation                                                                                                                                      MPS                       14 (mean; range 6--24)
  35                                                                                Vallier et al. \[[@pone.0233226.ref045]\]        87    CSS      1997--2006     B, C                                                          Nonoperative, external or internal fixation                                                                                                                      MFA                       41 (mean; range 16--137)
  36                                                                                Van Loon et al. \[[@pone.0233226.ref046]\]       32    CSS      1996--2008     B                                                             Nonoperative, external or internal fixation                                                                                                                      SF-36, MPS                84 (median)
  37                                                                                Wang et al. \[[@pone.0233226.ref047]\]           29    CSS      2010--2016     B, C                                                          Minimally invasive stabilization with pedicle screws connected to a transverse rod                                                                               MPS                       38 (mean; range 12--84)
  38                                                                                Wang et al. \[[@pone.0233226.ref048]\]           29    CS       2010--2016     B, C                                                          Modified pedicle screw-rod fixation                                                                                                                              MPS                       12
  39                                                                                Wu et al. \[[@pone.0233226.ref049]\]             23    CS       2013--2015     B, C                                                          Anterior fixation using a modified pedicle screw-rod fixator with or without posterior fixation using a transiliac internal fixator (TIFI)                       MPS                       10 (mean; range 4--12)
  40                                                                                Wu et al. \[[@pone.0233226.ref050]\]             44    RCT      2009--2012     B, C                                                          S:Internal fixation through minimally invasive adjustable plate (MIAP)                                                                                           MPS                       S: 27 (mean; range 13--48)
  C: internal fixation with locking compression plate (LCP)                         C: 22 (mean; range 12--42)                                                                                                                                                                                                                                                                                                              
  41                                                                                Yin et al. \[[@pone.0233226.ref051]\]            74    CCS      2015--2017     B, C                                                          S: Anterior subcutaneous internal fixator (INFIX)                                                                                                                MPS                       27 (mean; range 21--32)
  C: Plate fixation                                                                                                                                                                                                                                                                                                                                                                                                         
  42                                                                                Yu et al. \[[@pone.0233226.ref052]\]             51    CCS      \-             B                                                             S: reconstruction plate screw fixation                                                                                                                           MPS                       29 (mean; range 18--54)
  C: percutaneous cannulated screw fixation                                                                                                                                                                                                                                                                                                                                                                                 
  43                                                                                Zhang et al. \[[@pone.0233226.ref020]\]          42    CCS      2011--2017     Unilateral sacral fractures                                   S: lumbopelvic fixation                                                                                                                                          MPS                       12
  C: Novel adjustable plate                                                                                                                                                                                                                                                                                                                                                                                                 
  44                                                                                Zhang et al. \[[@pone.0233226.ref053]\]          22    CSS      2016--2017     B                                                             Nonoperative and operative                                                                                                                                       MPS                       12 (mean; range 8--15)
  45                                                                                Zhang et al. \[[@pone.0233226.ref021]\]          70    CCS      2009--2016     Unilateral zone II sacral fractures                           S: Sacroiliac screw                                                                                                                                              MPS                       25 (mean; SD 5)
  C: Minimally invasive adjustable plate                                                                                                                                                                                                                                                                                                                                                                                    
  46                                                                                Zhu et al. \[[@pone.0233226.ref054]\]            37    CS       2008--2012     B, C                                                          Ilioinguinal approach combined with a minimally invasive posterior approach                                                                                      MPS                       12

**\*** CSS, Cross-sectional study; RCT, randomized controlled trial; CS, cohort study; CCS, case-control study; S, study group; C, control group; IPS, Iowa Pelvic Score; VAS, visual Analog scale; SF-36, MOS 36-item Short Form Health Survey; SF-12, Short Form-12; EQ-5D, EuroQuol-5D.

^‡^ The Young-Burgess classification was translated to the AO/OTA classification.

Methodological quality assessment {#sec019}
---------------------------------

The results of the quality assessment of the included articles are presented in [Table 3](#pone.0233226.t003){ref-type="table"}. Total scores in percentages ranged between 50% and 92%. The average score was 72%. No studies were excluded based on this assessment. Most studies scored fairly positive on the first four areas, regarding citation (1), study purpose (2), relevant background literature (3), and description of the sample (4). None of the studies justified sample size (5), which is the reason that no studies scored the maximum amount of points on the assessment. In the RCT \[[@pone.0233226.ref050]\] randomization of groups was performed (6), but it was not clearly described by which method (7). The first eight studies used valid (8) and reliable (9) PROMs, though some used both valid PROMs and PROMs of which the validity was not established (+/-). The ten studies in the list with the lowest quality scores did often not report results in terms of statistical significance (10) and did not use appropriate analysis methods (11). The last three areas regarding clinical importance (12), dropouts (13) and appropriate conclusions (14) were mostly sufficiently described.

10.1371/journal.pone.0233226.t003

###### Scores of the quality assessment list ranged from best to worst score.
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                                                   No.   1    2    3    4    5    6    7    8     9     10   11   12   13   14   Total   \%
  ------------------------------------------------ ----- ---- ---- ---- ---- ---- ---- ---- ----- ----- ---- ---- ---- ---- ---- ------- ----
  Adelved et al. \[[@pone.0233226.ref023]\]        1     \+   \+   \+   \+   \-             \+    \+    \+   \+   \+   \+   \+   11/12   92
  Banierink et al. \[[@pone.0233226.ref012]\]      2     \+   \+   \+   \+   \-             \+    \+    \+   \+   \+   \+   \+   11/12   92
  Bott et al. \[[@pone.0233226.ref027]\]           3     \+   \+   \+   \+   \-             \+    \+    \+   \+   \+   \+   \+   11/12   92
  Hoch et al. \[[@pone.0233226.ref014]\]           4     \+   \+   \+   \+   \-             \+    \+    \+   \+   \+   \+   \+   11/12   92
  Hoffman et al. \[[@pone.0233226.ref013]\]        5     \+   \+   \+   \+   \-             \+    \+    \+   \+   \+   \+   \+   11/12   92
  Holstein et al. \[[@pone.0233226.ref015]\]       6     \+   \+   \+   \+   \-             \+    \+    \+   \+   \+   \+   \+   11/12   92
  Schmitz et al. \[[@pone.0233226.ref017]\]        7     \+   \+   \+   \+   \-             \+    \+    \+   \+   \+   \+   \+   11/12   92
  Vallier et al. \[[@pone.0233226.ref045]\]        8     \+   \+   \+   \+   \-             \+    \+    \+   \+   \+   \+   \+   11/12   92
  Brouwers et al. \[[@pone.0233226.ref010]\]       9     \+   \+   \+   \+   \-             +/-   +/-   \+   \+   \+   \+   \+   10/12   83
  Chen et al. \[[@pone.0233226.ref030]\]           10    \+   \+   \+   \+   \-             +/-   +/-   \+   \+   \+   \+   \+   10/12   83
  Frietman et al. \[[@pone.0233226.ref019]\]       11    \+   \+   \+   \+   \-             +/-   +/-   \+   \+   \+   \+   \+   10/12   83
  Lybrand et al. \[[@pone.0233226.ref039]\]        12    \+   \+   \+   \+   \-             +/-   +/-   \+   \+   \+   \+   \+   10/12   83
  Ma et al. \[[@pone.0233226.ref009]\]             13    \+   \+   \+   \+   \-             \-    \-    \+   \+   \+   \+   \+   10/12   83
  Muller et al. \[[@pone.0233226.ref040]\]         14    \+   \+   \+   \+   \-             +/-   +/-   \+   \+   \+   \+   \+   10/12   83
  Bastian et al. \[[@pone.0233226.ref024]\]        15    \+   \+   \+   \+   \-             \-    \-    \+   \+   \+   \+   \+   9/12    75
  Feng et al. \[[@pone.0233226.ref032]\]           16    \+   \+   \+   \+   \-             \-    \-    \+   \+   \+   \+   \+   9/12    75
  Kokubo et al. \[[@pone.0233226.ref035]\]         17    \+   \+   \+   \+   \-             \-    \-    \+   \+   \+   \+   \+   9/12    75
  Liu et al. \[[@pone.0233226.ref038]\]            18    \+   \+   \+   \+   \-             \-    \-    \+   \+   \+   \+   \+   9/12    75
  Park et al. \[[@pone.0233226.ref043]\]           19    \+   \+   \+   \+   \-             \-    \-    \+   \+   \+   \+   \+   9/12    75
  Shui et al. \[[@pone.0233226.ref011]\]           20    \+   \+   \+   \+   \-             \-    \-    \+   \+   \+   \+   \+   9/12    75
  Van Loon et al. \[[@pone.0233226.ref046]\]       21    \+   \+   \+   \+   \-             +/-   +/-   \-   \+   \+   \+   \+   9/12    75
  Wang et al. \[[@pone.0233226.ref048]\]           22    \+   \+   \+   \+   \-             \-    \-    \-   \-   \+   \+   \+   9/12    75
  Wang et al. \[[@pone.0233226.ref047]\]           23    \+   \+   \+   \+   \-             \-    \-    \+   \+   \+   \+   \+   9/12    75
  Yin et al. \[[@pone.0233226.ref051]\]            24    \+   \+   \+   \+   \-             \-    \-    \+   \+   \+   \+   \+   9/12    75
  Zhang et al. \[[@pone.0233226.ref020]\]          25    \+   \+   \+   \+   \-             \-    \-    \+   \+   \+   \+   \+   9/12    75
  Wu et al. \[[@pone.0233226.ref050]\]             26    \+   \+   \+   \+   \-   \+   \-   \-    \-    \+   \+   \+   \+   \+   10/14   71
  Bi et al. \[[@pone.0233226.ref025]\]             27    \+   \+   \+   \+   \-             \-    \-    \+   \-   \+   \+   \+   8/12    67
  Borozda et al. \[[@pone.0233226.ref026]\]        28    \+   \+   \+   \+   \-             \-    \-    \+   \+   \+   \-   \+   8/12    67
  Chen et al. \[[@pone.0233226.ref028]\]           29    \+   \+   \+   \+   \-             \-    \-    \+   \+   \+   \-   \+   8/12    67
  Chen et al. \[[@pone.0233226.ref029]\]           30    \+   \+   \+   \+   \-             \-    \-    \+   \-   \+   \+   \+   8/12    67
  Li et al. \[[@pone.0233226.ref036]\]             31    \+   \+   \+   \+   \-             \-    \-    \+   \+   \+   \-   \+   8/12    67
  Li et al. \[[@pone.0233226.ref037]\]             32    \+   \+   \+   \-   \-             \-    \-    \+   \+   \+   \+   \+   8/12    67
  Yu et al. \[[@pone.0233226.ref052]\]             33    \+   \+   \+   \-   \-             \-    \-    \+   \+   \+   \+   \+   8/12    67
  Zhang et al. \[[@pone.0233226.ref020]\]          34    \+   \+   \+   \+   \-             \-    \-    \+   \+   \+   \-   \+   8/12    67
  Dienstknecht et al. \[[@pone.0233226.ref031]\]   35    \+   \+   \+   \+   \-             \-    \-    \-   \-   \+   \+   \+   7/12    58
  Grubor et al. \[[@pone.0233226.ref018]\]         36    \+   \+   \-   \+   \-             \-    \-    \+   \+   \+   \-   \+   7/12    58
  Hua et al. \[[@pone.0233226.ref034]\]            37    \+   \+   \+   \+   \-             \-    \-    \-   \-   \+   \+   \+   7/12    58
  Schweitzer et al. \[[@pone.0233226.ref044]\]     38    \+   \+   \+   \+   \-             \-    \-    \-   \-   \+   \+   \+   7/12    58
  Wu et al. \[[@pone.0233226.ref055]\]             39    \+   \+   \+   \+   \-             \-    \-    \-   \-   \+   \+   \+   7/12    58
  Zhang et al. \[[@pone.0233226.ref021]\]          40    \+   \+   \+   \+   \-             \-    \-    \+   \-   \+   \-   \+   7/12    58
  Zhu et al. \[[@pone.0233226.ref054]\]            41    \+   \+   \+   \+   \-             \-    \-    \-   \-   \+   \+   \+   7/12    58
  Abishek et al. \[[@pone.0233226.ref022]\]        42    \+   \-   \+   \+   \-             \-    \-    \-   \-   \+   \+   \+   6/12    50
  Ayvaz et al. \[[@pone.0233226.ref008]\]          43    \+   \+   \-   \+   \-             +/-   +/-   \-   \-   \-   \+   \+   6/12    50
  Ghosh et al. \[[@pone.0233226.ref033]\]          44    \+   \-   \+   \+   \-             \-    \-    \+   \-   \+   \+   \-   6/12    50
  Nie et al. \[[@pone.0233226.ref041]\]            45    \+   \-   \+   \+   \-             \-    \-    \-   \-   \+   \+   \+   6/12    50
  Oh et al. \[[@pone.0233226.ref042]\]             46    \+   \+   \+   \+   \-             \-    \-    \-   \-   \+   \+   \+   6/12    50

Every plus sign means that the question was answered with 'yes'. Every minus sign means that a question was answered with 'no' or 'not addressed'. +/- was given in case both a valid as well as non-validated PROM was used and represents a score of 0.5. Questions 6 and 7 are only applicable for RCTs. The final two columns represent the total scores and percentages of maximal attainable scores (%).

Patient-reported outcome measures {#sec020}
---------------------------------

Thirty-eight studies \[[@pone.0233226.ref008],[@pone.0233226.ref009],[@pone.0233226.ref025],[@pone.0233226.ref026],[@pone.0233226.ref028]--[@pone.0233226.ref030],[@pone.0233226.ref032]--[@pone.0233226.ref036],[@pone.0233226.ref010],[@pone.0233226.ref037]--[@pone.0233226.ref044],[@pone.0233226.ref046],[@pone.0233226.ref047],[@pone.0233226.ref011],[@pone.0233226.ref048]--[@pone.0233226.ref054],[@pone.0233226.ref056],[@pone.0233226.ref018]--[@pone.0233226.ref022],[@pone.0233226.ref024]\] used a pelvic-specific PROM, either as a single instrument or in combination with a generic PROM. Generic PROMs for physical functioning and quality of life were used in 15 studies \[[@pone.0233226.ref008],[@pone.0233226.ref010],[@pone.0233226.ref039],[@pone.0233226.ref040],[@pone.0233226.ref046],[@pone.0233226.ref057],[@pone.0233226.ref058],[@pone.0233226.ref012],[@pone.0233226.ref013],[@pone.0233226.ref015],[@pone.0233226.ref017],[@pone.0233226.ref019],[@pone.0233226.ref023],[@pone.0233226.ref027],[@pone.0233226.ref030]\]. The follow-up moment when these questionnaires were assessed ranged from six months to 15 years after the injury. Scores on the PROMs per study are given in [Table 4](#pone.0233226.t004){ref-type="table"}.

10.1371/journal.pone.0233226.t004

###### Outcome of PROMs.

![](pone.0233226.t004){#pone.0233226.t004g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                Outcome of PROM at mean time of follow-up                                                                                                                                                                                                                                                                                                                               
  ----------------------------- ---------------------------------------------------------------------------------------- ------ ----- --------------------------------------------------------------- ------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------
  **MPS, N (%)**                                                                                                                                                                                                                                                                                                                                                                                        

                                Abhishek et al. \[[@pone.0233226.ref022]\]                                               2015   41                                                                    Excellent: 21 (51), Good: 13 (32)\                                                                                                                                                                
                                                                                                                                                                                                      Fair: 4 (10), Poor: 3 (7)                                                                                                                                                                         

                                Ayvaz et al. \[[@pone.0233226.ref008]\]                                                  2011   20                                                                                                                                                                     Mean 93.3 (range 72--100)\                                                                       
                                                                                                                                                                                                                                                                                                       Excellent: 19 (95), Good: 1 (5)\                                                                 
                                                                                                                                                                                                                                                                                                       Fair: -, Poor: -                                                                                 

                                Bastian et al. \[[@pone.0233226.ref024]\]                                                2016   63                                                                                                                                                                     Excellent: 37 (59), Good: 12 (19)\                                                               
                                                                                                                                                                                                                                                                                                       Fair: 9 (14), Poor: 5 (8)                                                                        

                                Bi et al. \[[@pone.0233226.ref025]\]                                                     2017   43                                                                    Mean 81.97 (range 64--94)\                                                                                                                                                                        
                                                                                                                                                                                                      Excellent: 19 (44), Good: 17 (40)\                                                                                                                                                                
                                                                                                                                                                                                      Fair: 7 (16), Poor: -                                                                                                                                                                             

                                Borozda et al. \[[@pone.0233226.ref026]\]                                                2015   28                                                                    Mean 81 (range 58--97) Excellent: 12 (43), Good: 11 (39)\                                                                                                                                         
                                                                                                                                                                                                      Fair: 4 (14), Poor: 1 (4)                                                                                                                                                                         

                                Brouwers et al. \[[@pone.0233226.ref010]\]                                               2018   195                                                                                                                                                                    Mean 76 (SD 14.8) Excellent: 119 (61), Good 52 (27)\                                             
                                                                                                                                                                                                                                                                                                       Fair: 17 (9), Poor: 7 (3)                                                                        

                                Chen et al. \[[@pone.0233226.ref028]\]                                                   2012   58                                                                    Mean: 80.7\                                                                                                                                                                                       
                                                                                                                                                                                                      Excellent: 19 (33), Good: 32 (55)\                                                                                                                                                                
                                                                                                                                                                                                      Fair: 7 (12), Poor: -                                                                                                                                                                             

                                Chen et al. \[[@pone.0233226.ref029]\]                                                   2013   21                                                                    Excellent: 15 (71), Good: 5 (24)\                                                                                                                                                                 
                                                                                                                                                                                                      Fair: 1 (5), Poor: -                                                                                                                                                                              

                                Chen et al. \[[@pone.0233226.ref030]\]                                                   2012   32                                                                    Excellent: 10 (31), Good: 8 (25)\                                                                                                                                                                 
                                                                                                                                                                                                      Fair: 8 (25), Poor: 6 (19)                                                                                                                                                                        

                                Feng et al. \[[@pone.0233226.ref032]\]                                                   2016   26                                                                    Excellent: 18 (69), Good: 7 (27)\                                                                                                                                                                 
                                                                                                                                                                                                      Fair: 1 (4), Poor: -                                                                                                                                                                              

                                Frietman et al. \[[@pone.0233226.ref019]\][†](#t004fn002){ref-type="table-fn"}           2016   37                                                                                                                                                                     Mean 75.3 (SD 19.5)                                                                              

                                Ghosh et al. \[[@pone.0233226.ref033]\]                                                  2018   75    Excellent: 27 (36), Good: 29 (39)\                                                                                                                                                                                                                                
                                                                                                                                      Fair: 12 (16), Poor: 7 (9)                                                                                                                                                                                                                                        

                                Hua et al. \[[@pone.0233226.ref034]\]                                                    2019   23                                                                    Excellent: 13 (57), Good: 6 (26)\                                                                                                                                                                 
                                                                                                                                                                                                      Fair: 4 (17), Poor: -                                                                                                                                                                             

                                Kokubo et al. \[[@pone.0233226.ref035]\]                                                 2017   82                                                                    Excellent + Good (satisfactory): 52 (63) Fair + Poor (Unsatisfactory): 30 (37)                                                                                                                    Excellent + Good (satisfactory): 70 (85) Fair + Poor (unsatisfactory): 12 (15)

                                Li et al. \[[@pone.0233226.ref036]\]                                                     2017   64                                                                    Excellent: 38 (60), Good: 13 (20)\                                                                                                                                                                Excellent: 36 (56), Good: 12 (19)\
                                                                                                                                                                                                      Fair: 13 (20), Poor: -                                                                                                                                                                            Fair: 16 (25), Poor: -

                                Li et al. \[[@pone.0233226.ref037]\]                                                     2018   47                                                                    Mean 80.2 (range 48--100)\                                                                                                                                                                        
                                                                                                                                                                                                      Excellent: 13 (28), Good: 30 (64)\                                                                                                                                                                
                                                                                                                                                                                                      Fair: 4 (8), Poor: -                                                                                                                                                                              

                                Liu et al. \[[@pone.0233226.ref038]\]                                                    2018   45    Mean 85.4 (SD 8.9)                                                                                                                                                                                                                                                

                                Lybrand et al. \[[@pone.0233226.ref039]\]                                                2017   54                                                                                                                                                                                                                                                                      Mean 76 (SD 17)

                                Ma et al. \[[@pone.0233226.ref009]\]                                                     2017   263   Excellent: 125 (48), Good: 67 (25 Fair: 53 (20), Poor: 18 (7)                                                                                                                                                                                                     

                                Nie et al. \[[@pone.0233226.ref041]\]                                                    2018   30    Excellent: 21 (70), Good: 9 (30)\                                                                                                                                                                                                                                 
                                                                                                                                      Fair: -, Poor: -                                                                                                                                                                                                                                                  

                                Park et al. \[[@pone.0233226.ref043]\]                                                   2017   64                                                                                                                                                                     Excellent: 31 (49), Good: 18 (28)\                                                               
                                                                                                                                                                                                                                                                                                       Fair: 11 (17), Poor: 4 (6)                                                                       

                                Schweitzer et al. \[[@pone.0233226.ref044]\]                                             2008   68                                                                                                                                                                     Excellent + good: 62 (91)\                                                                       
                                                                                                                                                                                                                                                                                                       Fair: 4 (6), Poor: 2 (3)                                                                         

                                Shui et al. \[[@pone.0233226.ref011]\]                                                   2015   117                                                                   Excellent: 48 (41), Good: 39 (33)\                                                                                                                                                                
                                                                                                                                                                                                      Fair: 24 (21), Poor: 6 (5)                                                                                                                                                                        

                                Van Loon et al. \[[@pone.0233226.ref046]\]                                               2011   32                                                                                                                                                                                                                                                                      Mean 95.7

                                Wang et al. \[[@pone.0233226.ref047]\]                                                   2017   29                                                                                                                                                                     Excellent: 10 (35), Good: 16 (55)\                                                               
                                                                                                                                                                                                                                                                                                       Fair: 3 (10), Poor: -                                                                            

                                Wang et al. \[[@pone.0233226.ref048]\]                                                   2018   29                                                                    Excellent: 15 (52), Good: 12 (41)\                                                                                                                                                                
                                                                                                                                                                                                      Fair: 2 (7), Poor: -                                                                                                                                                                              

                                Wu et al. \[[@pone.0233226.ref049]\]                                                     2018   23    Excellent: 14 (61), Good: 7 (30)\                                                                                                                                                                                                                                 
                                                                                                                                      Fair: 2 (8), Poor: -                                                                                                                                                                                                                                              

                                Wu et al. \[[@pone.0233226.ref050]\]                                                     2015   44                                                                                                                                                                     Mean 81.7 (SD 8.4)                                                                               

                                Yin et al. \[[@pone.0233226.ref051]\]                                                    2019   74                                                                                                                                                                     Mean 86.2 (SD 7)                                                                                 

                                Yu et al. \[[@pone.0233226.ref052]\]                                                     2015   51                                                                                                                                                                     Excellent: 36 (71), Good: 12 (24)\                                                               
                                                                                                                                                                                                                                                                                                       Fair: 3 (5), Poor: -                                                                             

                                Zhang et al. \[[@pone.0233226.ref020]\]                                                  2019   42                                                                    Excellent + Good (satisfactory): 33 (79)\                                                                                                                                                         
                                                                                                                                                                                                      Fair + Poor (Unsatisfactory): 9 (21)                                                                                                                                                              

                                Zhang et al. \[[@pone.0233226.ref053]\]                                                  2019   22                                                                    Mean 81 (SD 11)                                                                                                                                                                                   

                                Zhang et al. \[[@pone.0233226.ref021]\]                                                  2019   70                                                                                                                                                                     Excellent + Good (satisfactory): 56 (80)\                                                        
                                                                                                                                                                                                                                                                                                       Fair + Poor (Unsatisfactory): 14 (20)                                                            

                                Zhu et al. \[[@pone.0233226.ref054]\]                                                    2015   37                                                                    Excellent: 29 (78), Good: 8 (22)\                                                                                                                                                                 
                                                                                                                                                                                                      Fair: -, Poor: -                                                                                                                                                                                  

  **Iowa Pelvic Score (IPS)**                                                                                                                                                                                                                                                                                                                                                                           

                                Ayvaz et al. \[[@pone.0233226.ref008]\] [^†^](#t004fn002){ref-type="table-fn"}           2011   20                                                                                                                                                                     Mean 86 (range 82--90)\                                                                          
                                                                                                                                                                                                                                                                                                       Excellent: 11 (55)\                                                                              
                                                                                                                                                                                                                                                                                                       Good: 9 (45)                                                                                     

  **Pelvic Outcome Score**                                                                                                                                                                                                                                                                                                                                                                              

                                Dienstknecht et al. \[[@pone.0233226.ref031]\] [^\#^](#t004fn004){ref-type="table-fn"}   2011   62                                                                                                                                                                     Excellent: 19 (31), Good: 16 (26)\                                                               
                                                                                                                                                                                                                                                                                                       Fair: 25 (40), Poor: 2 (3)                                                                       

                                Muller et al. \[[@pone.0233226.ref040]\] [^\#^](#t004fn004){ref-type="table-fn"}         2013   36                                                                    Excellent: 9 (29), Good: 11 (35)\                                                                                                                                                                 
                                                                                                                                                                                                      Fair: 8 (26), Poor: 3 (10)                                                                                                                                                                        

  **Merle d'Aubigne-Postel**                                                                                                                                                                                                                                                                                                                                                                            

                                Grubor et al. \[[@pone.0233226.ref033]\] [^\#^](#t004fn004){ref-type="table-fn"}         2011   47                                                                    Excellent: 22 (47), Good: 15 (32)\                                                                                                                                                                
                                                                                                                                                                                                      Fair: 4 (9), Poor: 6 (12)                                                                                                                                                                         

                                Oh et al. \[[@pone.0233226.ref042]\] [^\#^](#t004fn004){ref-type="table-fn"}             2015   22                                                                    Excellent: 7 (32), Good: 12 (55)\                                                                                                                                                                 
                                                                                                                                                                                                      Fair: 3 (13), Poor: -                                                                                                                                                                             

  **MFA**                                                                                                                                                                                                                                                                                                                                                                                               

                                Vallier et al. \[[@pone.0233226.ref045]\] [^†^](#t004fn002){ref-type="table-fn"}         2012   87                                                                                                                                                                     Mean: 33 (22)                                                                                    

  **SMFA**                                                                                                                                                                                                                                                                                                                                                                                              

                                Banierink et al. \[[@pone.0233226.ref012]\]                                              2019   192                                                                                                                                                                    Function index: 22\                                                                              
                                                                                                                                                                                                                                                                                                       Bother index: 26\                                                                                
                                                                                                                                                                                                                                                                                                       Lower extremity: 21                                                                              

                                Hoffman et al. \[[@pone.0233226.ref013]\]                                                2012   119   Function index: 28\                                             Function index: 26\                                                                              Function index: 22\                                                                              
                                                                                                                                      Bother index: 31\                                               Bother index: 30\                                                                                Bother index: 24\                                                                                
                                                                                                                                      Lower extremity: 33                                             Lower extremity: 32                                                                              Lower extremity: 26                                                                              

  **SF-36**                                                                                                                                                                                                                                                                                                                                                                                             

                                Adelved et al. \[[@pone.0233226.ref023]\] [^†^](#t004fn002){ref-type="table-fn"}         2014   28                                                                    PF 62 (28), RP 42 (45), BP 51 (32), GH 65 (23), VT 47 (20), SF 69 (27), RE 62 (43), MH 67 (25)                                                                                                    PF 66 (26), RP 46 (45), BP 49 (29), GH 59 (26), VT 53 (23), SF 78 (22), RE 49 (44), MH 72 (21)

                                Ayvaz et al. \[[@pone.0233226.ref008]\]                                                  2011   18                                                                                                                                                                     BP: 3.3, GH: 4.4, SF: 7.9                                                                        

                                Bott et al. \[[@pone.0233226.ref027]\] [^†^](#t004fn002){ref-type="table-fn"}            2019   74                                                                    PF 69 (30), RP 68 (32), BP 62 (28), GH 59 (28), VT 53 (23), SF 75 (29), RE 78 (31), MH 70 (23)                                                                                                    

                                Chen et al. \[[@pone.0233226.ref030]\] [^†^](#t004fn002){ref-type="table-fn"}            2012   32                                                                    PF 53 (27), RP 24 (30), BP 50 (20), GH 42 (19), VT 46 (16), SF 52 (23), RE 50 (47), MH 52 (12)                                                                                                    

                                Frietman et al. \[[@pone.0233226.ref019]\] [^†^](#t004fn002){ref-type="table-fn"}        2016   37                                                                                                                                                                     PF 63 (26), RP 56 (41), BP 64 (27), GH 64 (25), VT 62 (30), SF 81 (24), RE 80 (32), MH 78 (18)   

                                Schmitz et al. \[[@pone.0233226.ref017]\] [^†^](#t004fn002){ref-type="table-fn"}         2018   55                                                                                                                                                                     PCS: 34 (8)\                                                                                     
                                                                                                                                                                                                                                                                                                       MCS: 45 (8)                                                                                      

                                Van Loon et al. \[[@pone.0233226.ref046]\]                                               2011   32                                                                                                                                                                                                                                                                      GH: 62, VT: 58, MH: 72, BP: 68, SF: 80, RE: 85, RP: 71, PF: 74

  **SF-12**                                                                                                                                                                                                                                                                                                                                                                                             

                                Hoch et al. \[[@pone.0233226.ref014]\] [\*](#t004fn001){ref-type="table-fn"}             2016   128                                                                                                                                                                    PCS 37 (11--56)\                                                                                 
                                                                                                                                                                                                                                                                                                       MCS 43 (21--66)                                                                                  

                                Muller et al. \[[@pone.0233226.ref040]\] [^†^](#t004fn002){ref-type="table-fn"}          2013   36                                                                    PCS 43 (2)\                                                                                                                                                                                       
                                                                                                                                                                                                      MCS 46 (2)                                                                                                                                                                                        

  **EQ-5D**                                                                                                                                                                                                                                                                                                                                                                                             

                                Banierink et al. \[[@pone.0233226.ref012]\] [\*](#t004fn001){ref-type="table-fn"}        2019   192                                                                                                                                                                    Mean 0.76 (-.134--1)                                                                             

                                Bott et al. \[[@pone.0233226.ref027]\] [^†^](#t004fn002){ref-type="table-fn"}            2019   74                                                                    Mean 0.71 (SD 0.3)                                                                                                                                                                                

                                Brouwers et al. \[[@pone.0233226.ref010]\] [^†^](#t004fn002){ref-type="table-fn"}        2019   195                                                                                                                                                                    Mean 0.78 (0.26)                                                                                 

                                Hoch et al. \[[@pone.0233226.ref014]\] [^†^](#t004fn002){ref-type="table-fn"}            2016   128                                                                                                                                                                    Mean 0.75 (0.14)                                                                                 

                                Holstein et al. \[[@pone.0233226.ref015]\][^‡^](#t004fn003){ref-type="table-fn"}         2013   172                                                                                                                                                                    Median: 0.78 (0.63--1.00)                                                                        

                                Lybrand et al. \[[@pone.0233226.ref039]\] [^†^](#t004fn002){ref-type="table-fn"}         2017   54                                                                                                                                                                                                                                                                      Mean 0.80 (0.20)

                                Schmitz et al. \[[@pone.0233226.ref017]\] [^†^](#t004fn002){ref-type="table-fn"}         2019   55                                                                                                                                                                     Mean 0.63 (0.28)                                                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Data are given as N (%). Abbreviations:\* Data given as mean (range).

^†^ Data given as mean (SD).

^‡^ Data given as median (IQR).

^\#^ Data given as N (%). S, study group; C, control group; IPS, Iowa Pelvic Score; VAS, visual Analog scale; SF-36, MOS 36-item Short Form Health Survey; PF, physical functioning; RP, role physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role emotional; MH, mental health; SF-12, Short Form-12; EQ-5D, EuroQuol-5D; MFA, Musculoskeletal function assessment; SMFA, Short Musculoskeletal Function Assessment

Patient-reported physical functioning {#sec021}
-------------------------------------

### PROMs results {#sec022}

Of the 34 studies \[[@pone.0233226.ref008],[@pone.0233226.ref009],[@pone.0233226.ref026],[@pone.0233226.ref028]--[@pone.0233226.ref030],[@pone.0233226.ref032]--[@pone.0233226.ref037],[@pone.0233226.ref010],[@pone.0233226.ref039],[@pone.0233226.ref041],[@pone.0233226.ref043],[@pone.0233226.ref044],[@pone.0233226.ref046]--[@pone.0233226.ref051],[@pone.0233226.ref011],[@pone.0233226.ref052]--[@pone.0233226.ref054],[@pone.0233226.ref019]--[@pone.0233226.ref022],[@pone.0233226.ref024],[@pone.0233226.ref025]\] that used the Majeed Pelvic Score (MPS), in 28 of them \[[@pone.0233226.ref009],[@pone.0233226.ref011],[@pone.0233226.ref032]--[@pone.0233226.ref038],[@pone.0233226.ref041],[@pone.0233226.ref043],[@pone.0233226.ref044],[@pone.0233226.ref020],[@pone.0233226.ref047]--[@pone.0233226.ref054],[@pone.0233226.ref021],[@pone.0233226.ref022],[@pone.0233226.ref024]--[@pone.0233226.ref026],[@pone.0233226.ref028],[@pone.0233226.ref029]\] it was the only outcome instrument used. Most studies described the results in terms of the clinical grade. These were 'excellent' in 28--95% of the patients, 'good' in 5--64%, 'fair' in 0--25% and 'poor' in 0--19% of patients. Seven studies \[[@pone.0233226.ref019],[@pone.0233226.ref038],[@pone.0233226.ref039],[@pone.0233226.ref046],[@pone.0233226.ref050],[@pone.0233226.ref051],[@pone.0233226.ref053]\] only described the mean, ranging from 75 up to 95. Three studies \[[@pone.0233226.ref020],[@pone.0233226.ref021],[@pone.0233226.ref035]\] combined 'excellent' and 'good' results to 'satisfactory' (range 56--85%) and 'poor' and 'fair' to 'unsatisfactory' (range 15--37%). The Iowa Pelvic Score (IPS) was used by one study \[[@pone.0233226.ref008]\]. The mean score was 86 (range 82--90). The Pelvic Outcome Score (POS) was used by two authors \[[@pone.0233226.ref031],[@pone.0233226.ref040]\]. The rates for 'excellent' in both studies were 29% and 31%, for 'good' 26% and 35%, for 'fair' 26% and 40% and for 'poor' 3% and 10%. Two studies \[[@pone.0233226.ref018],[@pone.0233226.ref042]\] used the Merle D' Aubigne-Postel score for evaluation of function after pelvic ring injuries and graded it into 'excellent' (32% and 47%), 'good' (32% and 55%), 'fair' (9% and 13%), and 'poor' (0% and 12%). The Musculoskeletal Function Assessment (MFA) was used by only one study \[[@pone.0233226.ref045]\] evaluating female patients treated for pelvic ring injury. The mean score was 33 (SD 22). The Short Musculoskeletal Function Assessment (SMFA) was used in two studies \[[@pone.0233226.ref012],[@pone.0233226.ref013]\]. One study \[[@pone.0233226.ref012]\] reported a score of 22 on the function index, 26 on the bother index and 21 on the lower extremity subscale. The other study \[[@pone.0233226.ref013]\] evaluated the scores of the SMFA on three time points (6, 12 and 24 months). Subsequently, scores on the function index were 28, 26 and 22, on the bother index 31, 30 and 24, and 33, 32 and 26 on the lower extremity subscale.

### Changes in physical functioning {#sec023}

Three studies described physical functioning at different time points, and almost all of them showed improved scores at a later stage. Kokubo et al. \[[@pone.0233226.ref035]\] applied the MPS at one year and once again after a mean of 7.4 years, while Li et al. \[[@pone.0233226.ref036]\] also applied the MPS at one year and 10 years after the injury. Kokubo et al. found satisfactory (excellent + good) results of 63% after 1 year and 85% after 7.4 years. Unsatisfactory (fair + poor) results were found in 37% at one year and 15% after 7.4 years. Li et al. found excellent results in 60% after one year and 56% after 10 years, good results in 20 and 19%, fair in 20 and 25%, and no poor results. Hoffman et al. \[[@pone.0233226.ref013]\] used the SMFA at 6, 12 and 24 months revealing consecutive scores of 28, 26 and 22 on the function index, 31, 30 and 24 on the bother index and 33, 32 and 26 on the lower extremity subscale.

Patient-reported quality of life {#sec024}
--------------------------------

### PROMs results {#sec025}

The SF-36 was used in seven studies \[[@pone.0233226.ref008],[@pone.0233226.ref017],[@pone.0233226.ref019],[@pone.0233226.ref023],[@pone.0233226.ref027],[@pone.0233226.ref030],[@pone.0233226.ref046]\]. Five studies \[[@pone.0233226.ref019],[@pone.0233226.ref023],[@pone.0233226.ref027],[@pone.0233226.ref030],[@pone.0233226.ref046]\] described all eight components of the SF-36 and one study \[[@pone.0233226.ref008]\] only described three of them. Scores ranged from 53 up to 69 (physical functioning), 24 to 71 (role physical), 49 to 68 (bodily pain), 42 to 65 (general health), 46 to 62 (vitality), 52 to 81 (social functioning), 49 to 85 (role emotional) and 52 to 78 (mental health). One study \[[@pone.0233226.ref017]\] only described the PCS and MCS score, which was 34 and 45 respectively. The SF-12 was used by two authors \[[@pone.0233226.ref014],[@pone.0233226.ref040]\]. The scores on the PCS were 37 and 43, and the scores on the MCS 43 and 46. The EQ-5D for the evaluation of quality of life was used in seven studies \[[@pone.0233226.ref010],[@pone.0233226.ref012],[@pone.0233226.ref014],[@pone.0233226.ref015],[@pone.0233226.ref017],[@pone.0233226.ref027],[@pone.0233226.ref039]\]. Mean scores ranged from 0.63 to 0.80.

### Changes in quality of life {#sec026}

Only one study \[[@pone.0233226.ref023]\] assessed the SF-36 twice, at one year and once again after a mean of 10.7 years. Most of the scores improved after an interval of 10 years, although some decreased. Consecutive scores were as follows: physical functioning: 62 and 66, 42 and 46 (role physical), 51 and 49 (bodily pain), 65 and 59 (general health), 47 and 53 (vitality), 69 and 78 (social functioning), 62 and 49 (role emotional), 67 and 72 (mental health).

Discussion {#sec027}
==========

The management of and recovery of pelvic ring injuries has had gained attention over the years by clinicians and researchers. Although the focus primary laid on radiographic outcomes over the past decades, more recently this focus shifted towards the use of patient-reported outcome measures (PROMs). This is the first systematic review to evaluate outcomes in terms of physical functioning and quality of life after pelvic ring injuries. The extensive literature search resulted in the inclusion of 46 studies regarding patients with a broad range of injury types and treatment methods. Physical functioning and quality of life was mainly assessed between one and five years after pelvic ring injury. Most studies had small sample sizes, with more than half including even less than 50 patients. Besides, the quality of the studies was moderate to poor. Nine different outcome measures were used; 38 studies used disease-specific PROMs and 15 studies used generic PROMs. None of the disease-specific PROMs have been proven valid for use in patients with pelvic ring injuries. Overall, the recovery of physical functioning and quality of life following pelvic ring injuries seemed fair, although the reported results varied widely between studies and the different PROMs. Taking all of the above into account, it is challenging to conclude an overall result in terms of physical functioning and quality of life after pelvic ring injuries. Hence, some critical remarks can be made on the included studies based on the results of this systematic review.

Most studies reported on a wide variety of pelvic ring injury types. According to the AO/OTA classification system \[[@pone.0233226.ref016]\], pelvic ring injuries can be divided into type A, B or C injuries. However, sometimes the Young-Burgess classification \[[@pone.0233226.ref059]\] was used, which divides these injuries into 'anterior posterior compression (APC)', 'lateral compression (LC)' or 'vertical shear injuries (VS)'. In the studies that were included in this systematic review, it was not always clear what type of injury the patients had and most studies did not differentiate in the outcomes between for example B and C type injuries. Although type B as well as type C injuries are considered to be unstable fractures, type B injuries are simply rotationally unstable and therefore more likely to result in good outcomes, compared to the rotationally as well as vertically unstable type C injuries. Also, type A injuries were only assessed in six studies \[[@pone.0233226.ref010],[@pone.0233226.ref012],[@pone.0233226.ref015],[@pone.0233226.ref017]--[@pone.0233226.ref019]\] even though this type consists most of all types of pelvic ring injuries \[[@pone.0233226.ref012]\]. Moreover, there was no differentiation in outcomes of patients with solely a pelvic ring injury, and of patients with multiple injuries, which is seen in polytrauma patients. This may clearly affect results of generic PROMs.

None of the studies focused solely on the outcomes after nonoperative treatment of pelvic ring injuries. Only a few of the included studies \[[@pone.0233226.ref010],[@pone.0233226.ref012],[@pone.0233226.ref053],[@pone.0233226.ref057],[@pone.0233226.ref060],[@pone.0233226.ref013]--[@pone.0233226.ref015],[@pone.0233226.ref017],[@pone.0233226.ref018],[@pone.0233226.ref033],[@pone.0233226.ref035],[@pone.0233226.ref046]\] evaluated outcomes of patients that were treated either operatively or nonoperatively, while most studies only assessed operatively treated patients. Moreover, among the operatively treated patients, a wide variety of surgical techniques was used. The used techniques varied from external fixation, to purely anterior or posterior fixation, to a combination of both and even experimental techniques for specific pelvic ring injury types. Due to this variety in applied surgical techniques, which were often also poorly described, it was not possible to perform subgroup analyses. After all, the aim of this systematic review was to provide a general assessment of outcomes after pelvic ring injuries, but not of any specific operative approach.

Follow-up was mainly assessed between one and five years, missing the important short-term (\<12 months) as well as long-term (\>5 years) consequences of these injuries on the patients' daily life. Especially in the studies evaluating surgical techniques, the short-term follow-up is highly important, as this is a critical period in which the most improvement in physical functioning can be achieved. On the other hand, long-term follow-up might be just as important, revealing the late complications like gait impairment, chronic pelvic and back pain as well as delayed consequences of lumbosacral plexus injury \[[@pone.0233226.ref061]\]. Also, the unknown pre-injury condition for physical functioning and quality of life leaves us guessing about the actual effect of the injury on the patients daily life.

Another problem in the evaluation of the studies was that the sample sizes of most studies were small, often including even less than 50 patients (N = 24). The methodological quality assessment revealed that no sample size calculation was performed in each of the studies, which makes it arguable whether enough patients were included to draw conclusions from in terms of physical functioning and quality of life. The quality assessment also revealed that, overall, the methodological quality was moderate and did not reach perfection in any of the studies, as all missed the justification for sample size. Moreover, many studies failed to achieve higher scores due to the use of nonvalidated outcome measures like the MPS.

The use of nine different PROMs was another issue. Of the four different disease-specific PROMs, the MPS was by far the most frequently used PROM in 34 studies, even though it has never been validated in patients with pelvic ring injuries. The reason for its frequent use could be explained by the compact length of the questionnaire and the possibility to compare outcomes to those of other studies. Similar to the results of this review, Lefaivre et al. showed that the MPS is the most commonly used pelvic outcome score \[[@pone.0233226.ref005]\]. Results were most often graded as 'excellent', although there was a wide variation in the proportion of patients that had an excellent score between the various studies. Only three studies \[[@pone.0233226.ref012],[@pone.0233226.ref013],[@pone.0233226.ref057]\] used two different generic PROMs (MFA and SMFA) to assess physical functioning, while quality of life was assessed in 13 different studies using the SF-12, SF-36 and EQ-5D, showing acceptable quality of life following pelvic ring injuries. The asset of these generic questionnaires is the availability of normative data to compare results with. A complicating factor was that the scores on identical questionnaires were often reported in different ways, making them hardly comparable. For example, the results on the MPS of the SF-36 were frequently reported by the categories (excellent, good etcetera), whereas other studies only presented mean scores with standard deviation, range, or a combination of these. In addition, scores varied widely, even between studies that used the same PROMs.

None of the disease-specific questionnaires that were used have been proven to be valid to assess physical functioning of patients with pelvic ring injuries, while all generic outcome instruments have. The ability of the outcomes of PROMs to improve decision-making in clinical research relies on the psychometric strength of the instrument to capture the burden of disease or treatment. Reliability and validity are separate psychometric properties, both essential for any measure \[[@pone.0233226.ref062]\]. Measures can be highly reliable but not measure what they are supposed to measure \[[@pone.0233226.ref063]\]. Some studies compared pelvic-specific PROMs with generic PROMs to investigate the validity of disease-specific instruments in examining pelvic-specific areas, but failed to do so \[[@pone.0233226.ref005],[@pone.0233226.ref064]--[@pone.0233226.ref066]\]. Hence, until there is a disease-specific questionnaire for pelvic ring injuries that is proven to be valid and reliable, it seems preferable to use a reliable and valid generic PROM to assess physical functioning and quality of life following these injuries. Another advantage of the latter is that, for these generic PROMs normative data often available is.

PROMs enable important clinical questions to be answered in clinical research \[[@pone.0233226.ref003]\]. Its use should be integrated in the clinical evaluation of a patient with pelvic ring injuries, next to the more objective measures like radiographic outcomes, because PROMs directly reflect the patients' perspective on the impact of their injury on daily life. Some types of pelvic injuries may look highly unfavourable on radiographic imaging, but the patient may grade his physical functioning and quality of life fairly well, or the other way around. Despite the fact that there has been discussion on the actual contribution of PROMs to the improvement of patient care, these instruments have the potential to facilitate patient involvement in treatment decision-making and provide guidance for health-care decisions \[[@pone.0233226.ref063]\]. Patients may monitor their health status over time and eventually will be more actively engaged in striving for health outcomes like full rehabilitation. Also, PROMs may help clinicians quickly identify which of their patients experience improved or deteriorated health outcomes. This may help to identify any structural patient complaints, which would suggest that refinements to care pathways might be needed. However, at this moment, PROMs function more as a tool for the use in clinical research, than they do in substantially changing medical practice.

Strengths and limitations {#sec028}
-------------------------

Some strengths and limitations of this systematic review and its conclusions need to be addressed. To start with, this is the first systematic review to evaluate patient-reported physical functioning and quality of life after pelvic ring injuries. Also, search criteria were not limited by the type of study (e.g. cohort study, RCT), which provided a complete overview of all study results published during the past decade. Moreover, this systematic review underlines that some changes are needed in the future in order to examine the true consequences of pelvic ring injuries on the patients' daily life, for example to only use reliable and valid patient-reported outcome instruments. In this systematic review, a highly sensitive comprehensive search was conducted following the recommendations of an experienced medical librarian in order to identify articles of interest. For practical reasons though, only studies published in English, German, Spanish, French or Dutch were included in the final review, which might have led to selection bias. Additionally, studies published before 2008 were excluded after consultation with two experienced pelvic trauma surgeons. The argument for this was that, before 2008, treatment methods differed such an extent that including studies published before that time might lead to bias in the results of this systematic review. In this review, we included all types of pelvic ring injuries, treatment methods and types of PROMs. Due to this heterogeneity, individual outcomes of the included studies were not suitable for reliable comparisons. At last, sample sizes were not justified in any of the included studies.

Conclusion {#sec029}
----------

Even though the above-mentioned critical remarks make it ambitious to draw conclusions in terms of physical functioning and quality of life after pelvic ring injuries, the results imply that patients' physical functioning and quality of life seem reasonably fair and improve over time. However, a heterogeneous group of studies was presented, including small cohorts of patients with a wide range of injury types, treatment methods and diverse, often nonvalidated, outcome measures. Hence, there is a high need to use a valid and reliable outcome measure to evaluate and compare the recovery in terms of physical functioning and quality of life after pelvic ring injuries on large groups of patients. The following section provides some guidance for future research.

Practical implications and recommendations for future research regarding use of PROMs after pelvic ring injuries {#sec030}
----------------------------------------------------------------------------------------------------------------

-   Authors should clearly define the injury type according to the AO/OTA classification and distinguish between outcomes of different types of injuries. They should also distinguish between a pelvic ring injury as the only injury or as part of multiple injuries.

-   Prospective longitudinal studies are needed with sufficient number of patients and multiple time intervals at short-term as well as long-term (\>5 years) follow-up.

-   (Recalled) pre-injury status of physical functioning and quality of life should be recorded.

-   Only valid and reliable PROMs should be used, for example the SMFA for physical functioning and the EQ-5D or SF-36 for quality of life. These PROMs can be compared with age-specific norm data of the general population. The use of non-validated pelvic-specific PROMs should be avoided.

-   There is still a challenging and a necessary task to validate existing pelvic-specific PROMs and develop an uniform PROM for pelvic injuries worldwide.

Supporting information {#sec031}
======================

###### Description of the included PROMs.

(DOCX)

###### 

Click here for additional data file.

###### 

(DOC)

###### 

Click here for additional data file.

We thank Truus van Ittersum for helping with the search strategy.
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Dear members of the editorial board,

Thank you for your important remarks on our manuscript. We will address each of your points in the following section:

Methods section

1\. Page 11, line 95: please write inclusion instead of "In."

Done

Results section

1\. All case either treated with operative or non-operative treatment ways were included, there are no data presented to compare between those types of patients regarding PROMs

This is right. In this study we wanted to provide an overview of all available outcomes and not compare types of treatment. Of course this would be interesting, but with all the different operative techniques that were used, as well as outcome measures, the results of this comparison would not be valid.

2\. Page 13, line 157: in the sentence (conducted January 2008 to April 15th 2019) write "from" after conducted.

Done

3\. line169: write the reference after " AO classification system"

Done

4\. It's better to insert the tables of results in the main manuscript better than additional files, as they are an integral part of the manuscript

We agreed and added the tables in the main manuscript

Limitations section

1\. Please include the non-calculation of the sample size in all studies.

Done

2\. Also, gathering of data with multiple tools of assessment is a major limitation.

This is also added in the limitations section, together with the fact that it includes all types of pelvic ring injuries and treatment methods.

We hope to have answered all of your questions and managed to correctly address all of your remarks in the revised manuscript.

Hester Banierink,

On behalf of all authors
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We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Osama Farouk

Academic Editor

PLOS ONE
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#3: No
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Dear Dr. Banierink:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Osama Farouk

Academic Editor

PLOS ONE
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